title: The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS).
abstract: The majority of the drugs currently used for the treatment of HIV infections (AIDS) belong to either of the following three classes: nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs). At present, there are 7 NRTIs, 5 NNRTIs, and 10 PIs approved for clinical use. They are discussed from the following viewpoints: (i) chemical formulae; (ii) mechanism of action; (iii) drug combinations; (iv) clinical aspects; (v) preexposure prophylaxis; (vi) prevention of mother-to-child transmission; (vii) their use in children; (viii) toxicity; (ix) adherence (compliance); (x) resistance; (xi) new NRTIs, NNRTIs, or PIs in (pre)clinical development; and (xii) the prospects for a "cure" of the disease.
authors.affiliation: Rega Institute for Medical Research, KU Leuven, Leuven, Belgium. erik.declercq@rega.kuleuven.be
authors.forename: Erik
authors.initials: E
authors.lastname: De Clercq
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000821:virology; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D018562:Disease Transmission, Infectious / Q000517:prevention & control; D024882:Drug Resistance, Viral; D015507:Drugs, Investigational / Q000627:therapeutic use; D006678:HIV / Q000187:drug effects* / Q000201:enzymology*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D055118:Medication Adherence; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D015507:Drugs, Investigational; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors
keywords: AIDS; HIV; NNRTIs; NRTIs; PIs